How to buy iBio (IBIO) shares in Australia
Learn how to easily invest in iBio shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
iBio Inc is a biotechnology business with stocks listed in the US. iBio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was US$0.52 – the same closing value as a week prior. Here's how to invest if you're based in Australia.
How to buy shares in iBio
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for iBio. Find the share by name or ticker symbol: IBIO. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until iBio reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$0.52, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of iBio, depending on your broker.
- Check in on your investment. Congratulations, you own a part of iBio. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
iBio stock price (NYSE MKT:IBIO)Use our graph to track the performance of IBIO stocks over time.
iBio shares at a glance
|52-week range||US$0.481 - US$2.83|
|50-day moving average||US$0.6612|
|200-day moving average||US$1.1206|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$-0.119|
Where to buy iBio stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy iBio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
iBio price performance over time
|1 week (2022-01-12)||4.00%|
|1 month (2021-12-17)||-21.00%|
|3 months (2021-10-19)||-42.22%|
|6 months (2021-07-19)||-63.12%|
|1 year (2021-01-19)||-65.56%|
|2 years (2020-01-17)||121.37%|
|3 years (2019-01-18)||-40.23%|
|5 years (2017-01-18)||-86.67%|
Stocks similar to iBio
|Revenue TTM||US$2.2 million|
|Gross profit TTM||US$909,000|
|Return on assets TTM||-15.81%|
|Return on equity TTM||-27.27%|
|Market capitalisation||US$112.2 million|
TTM: trailing 12 months
iBio share dividends
We're not expecting iBio to pay a dividend over the next 12 months.
Have iBio's shares ever split?
iBio's shares were split on a 1:10 basis on 10 June 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iBio shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for iBio shares which in turn could have impacted iBio's share price.
iBio share price volatility
Over the last 12 months, iBio's shares have ranged in value from as little as US$0.481 up to US$2.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while iBio's is -6.0172. This would suggest that iBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, iBio has bucked the trend.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
iBio in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Joe Manchin's former aides gain influential lobbying clients as their ex-boss battles Biden's agenda
Frequently asked questions
More guides on Finder
RAT scams: How to avoid getting conned with rapid antigen tests
Don't fall for the scam artists when you're trying to protect your health - here's what to check.
How to do a COVID-19 test at home for international travel
Here's where you can book COVID-19 at-home tests approved for travel and how they work.
Where to shop every product in Kiernan Shipka’s beauty routine
We've rounded up everything you need to nail the 'date-worthy' makeup look, including some affordable dupes.
American Express Corporate Gold Card
Designed for big companies, this Amex charge card offers a mix of management tools and perks – including a 100,000 bonus Membership Rewards offer.
Rapid antigen tests: When will RAT stock be available? [UPDATED]
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
Beauty Product of the Week: Milk Makeup Hydro Grip Primer
We tried the viral Milk Makeup Hydro Grip Primer and spoiler alert, it's the bee's knees.
Where to watch Hotel Transylvania 4 online for free in Australia
Drac and the Pack are back, like you’ve never seen them before.
Dyson V12 Detect Slim review: Baby love, my baby love
A delightful compact vacuum with an unjustifiable price.
Stan Event: Streaming platform joins pay-per-view ranks
A new player enters the Australian sports broadcast market.
Amazon Echo Buds (2nd Gen) review: Fine if you’re already trapped by Bezos
The Amazon Echo Buds 2 are a solid addition to your earholes if you’re already integrated in the Alexa ecosystem. But if you’re not, its hard to find anything here that really stands out.
Ask an Expert